



The University of Manchester Research

Feasibility of an Intervention to Support Hearing and Vision in Dementia

DOI: 10.1111/jgs.15936

Document Version

Accepted author manuscript

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Hooper, E., Simkin, Z., Abrams, H., Camacho, E., Charalambous, A. P., Collin, F., Constantinidou, F., Dawes, P., Elliott, R., Falkingham, S., Frison, E., Hann, M., Helmer, C., Himmelsbach, I., Hussain, H., Marié, S., Montecelo, S., Reeves, D., Regan, J., ... Leroi, I. (2019). Feasibility of an Intervention to Support Hearing and Vision in Dementia: The SENSE-Cog Field Trial. *Journal of the American Geriatrics Society*. https://doi.org/10.1111/jgs.15936

Published in:

Journal of the American Geriatrics Society

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.



1 Feasibility of an intervention to support hearing and vision in dementia: 2 **The SENSE-Cog Field Trial** 3 Emma Hooper,¹ Zoe Simkin¹, Harvey Abrams², Elizabeth Camacho³, Anna Pavlina 4 Charalambous⁴, Fideline Collin⁵, Fofi Constantinidou⁴, Piers Dawes⁶, Rachel Elliott³, Sue 5 Falkingham⁷, Eric Frison⁵, Mark Hann⁸, Catherine Helmer⁹, Ines Himmelsbach¹⁰, Hannah 6 Hussain³, Sarah Marié¹¹, Susana Montecelo¹¹, David Reeves⁸, Jemma Regan¹², Chryssoula 7 Thodi⁴, Lucas Wolski⁹, Iracema Leroi^{1,13, 14} 8 9 ¹ Division of Neuroscience and Experimental Psychology, University of Manchester, U.K. ² University of South Florida, Tampa, Florida, USA 10 ³ Manchester Centre for Health Economics, University of Manchester, U.K. 11 ⁴ Department of Health Sciences, School of Sciences, European University Cyprus, Nicosia, 12 Cyprus 13 ⁵ University of Bordeaux, INSERM, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux 14 Population Health Center, France 15 ⁶ Manchester Centre for Audiology and Deafness, University of Manchester, U.K. 16 ⁷ Starkey Hearing technologies, U.K. 17 ⁸ Centre for Biostatistics, University of Manchester, U.K. 18 ⁹ University of Bordeaux, INSERM, Bordeaux Population Health Research Center, team LEHA, 19 20 France ¹⁰ Catholic University of Applied Sciences Freiburg, Freiburg, Germany 21 ¹¹Essilor International, Research & Development, Paris, France 22 ¹² Research Associate, University of Manchester, UK 23 ¹³ Global Brain Health Institute, Trinity College Dublin, Ireland 24

- 25 ¹⁴ Greater Manchester Mental Health Foundation Trust, UK
- 26 (Please note that the first two names are joint first authors; the final author is the senior author; all
- 27 other authors are in alphabetical order)
- 28 ***Corresponding author:**
- 29 Iracema Leroi
- 30 Global Brain Health Institute
- 31 Room 0.60, Lloyd Building
- 32 Trinity College Dublin
- 33 Dublin 2, Ireland
- 34 +353 (0) 1 896 8500
- 35 Email: iracema.leroi@manchester.ac.uk
- 36
- 37 Running head: Feasibility of sensory support in dementia
- 38 This paper was first presented as part of a symposium at the British Society of Gerontology
- 39 Annual meeting in Manchester, 5th July 2018.
- 40
- 41 Word count:
- 42 Abstract: 300; Main text: 2333; 2 tables; 1 figure; 1 supplementary table; 28 references.
- 43 Keywords: Dementia, hearing impairment, vision impairment, feasibility, acceptability,
- 44 tolerability.

Trial registration number: The trial is a psychosocial intervention with an allocated ISRCTN
 46 number 35019114 16th January 2018

Impact statement: We certify that this work is entirely novel and is the first study of hearing
and vision enhancement in people living with dementia. This interdisciplinary approach
makes a significant contribution to the literature and sets the stage for further full scale
evaluations of hearing and vision interventions to improve outcomes for people with
dementia. This is the first part of a two-part report.

52 Abstract

53	Background: People living with dementia (PwD) frequently experience hearing and vision
54	impairment that is under-recognised and under-treated, resulting in reduced quality of life.
55	Managing these impairments may be an important strategy to improve outcomes in PwD.
56	Objective: To field trial a multi-faceted 'Sensory Intervention' (SI) to enhance hearing and
57	vision in PwD.
58	Design: An international single arm, open label, feasibility, acceptability and tolerability
59	study.
60	Setting: Home-based, in the United Kingdom, France, and Cyprus.
61	Participants: Adults aged \geq 60 with mild-moderate dementia and uncorrected or sub-
62	optimally corrected hearing and/or vision impairment, and their study partners (n=19
63	dyads).
64	Intervention: A 'Sensory Intervention' (SI), comprising assessment of hearing and vision,
65	fitting of corrective devices (glasses, hearing aids), and home-based support from a 'sensory
66	support therapist' for device adherence and maintenance, communication training, referral
67	to support services, environmental sensory modification and optimisation of social
68	inclusion.
69	Measurements: Ratings of study procedure feasibility, and intervention
70	acceptability/tolerability, ascertained through questionnaires, participant diaries, therapist
71	logbooks and semi-structured interviews.
72	

73	Results: We successfully delivered all intervention components, and these were received
74	and enacted as intended in all those who completed the intervention. No serious adverse
75	events were reported. Acceptability (i.e. understanding, motivation, sense of achievement)
76	and tolerability (i.e. effort, fatigue) ratings of the intervention were within a priori target
77	ranges. We met recruitment and retention (93.8%) targets in two of the three sites.
78	Participants completed >95% of diary entries, representing minimal missing data. Delays in
79	the logistics circuit for the assessment and delivery of hearing aids and glasses were
80	identified, requiring modification. The need for minor modifications to some outcome
81	measures and the inclusion criteria were identified.
82	
83	Conclusion: This is the first study combining home-based hearing and vision remediation in
84	PwD and the positive feasibility, acceptability and tolerability findings suggest that a full-

85 scale efficacy trial, with certain modifications, is achievable.

86 Introduction

People with dementia (PwD) are more likely to experience vision and hearing impairment 87 than their healthy counterparts ^{1,2}, and such impairments, particularly in combination, may 88 impact negatively on quality of life³ and other outcomes^{4,5}, as well as imposing an additional 89 burden on health, social and informal care ^{6,7}. Importantly, there is some evidence that 90 managing vision and hearing impairments with glasses and hearing aids respectively may 91 improve outcomes⁸ but the evidence is still equivocal and represents a gap in 92 understanding. Unfortunately, in the context of dementia, adherence to hearing aids and 93 other devices is often low⁹. Thus, simply correcting the sensory impairment may be 94 insufficient to have a positive impact. In contrast, an intervention targeting the wider issue 95 of sensory impairment and adherence with corrective devices may have a role. To address 96 this, we iteratively developed a multi-faceted 'sensory intervention' (SI) which includes 97 98 assessment and management of hearing and vision deficits and additional support to aid adoption of the corrective devices into everyday life as well other components to support 99 sensory function³. 100

101

A first step in evaluating a complex psychosocial intervention should be a field trial of the
study design, components and implementation of the intervention¹⁰. Thus, the primary aim
of our field trial was to evaluate: (1) the feasibility of the operational aspects of an
evaluation trial of the intervention; and (2) the acceptability and tolerability of the
intervention. Our secondary aim was to explore a signal of clinical and cost effectiveness,
which we report elsewhere (in preparation). The results of this study have informed the

design and conduct of a full-scale randomised controlled trial (RCT) in five European sites
 (ISRCTN 17056211)¹¹.

110

111 Methods

112 Study design and participants

113 This was an international single-arm, open-label field study of a newly developed 'sensory intervention' to improve the hearing and/or vision of PwD in three sites: Bordeaux, France 114 (Site B), Manchester, UK (Site M) and Nicosia, Cyprus (Site N). The study received favourable 115 116 ethical opinion at each site. All participants provided written informed consent prior to their 117 inclusion. The planned sample size was n=24 dyads (PwD and study partner), with 8 dyads per site. All dyads received the basic version of the SI, with a sub-set of 4 receiving a 12-118 week extended version. We recruited participants from memory assessment clinics, and 119 dementia research registries such as Join Dementia Research in the UK¹². Detailed inclusion 120 and exclusion criteria have been described elsewhere¹³. Briefly, these included people over 121 122 the age of 60, living at home with a formal diagnosis of mild-moderate stage dementia (Alzheimer disease, vascular dementia or 'mixed' Alzheimer and vascular dementia) and 123 with capacity to consent (as per the UK's Mental Capacity Act, 2005)¹⁴. All had a clinically 124 125 significant uncorrected or partially corrected (e.g. outdated prescription for sensory aids) hearing and/or vision problem, ascertained using a brief objective screening procedure. The 126 inclusion threshold for hearing was >35 dB HL over 1-3 kHz and above in the better ear, and 127 for vision was binocular corrected visual acuity of $\leq 6/9$, 5 Snellen metric or $\geq +0,2$ LogMAR 128 129 and a visual field of >/=10^o. We did not include people with congenital hearing and/or vision impairments. Study partners were informal carers in regular contact with the PwD. 130

132

[Insert Table 1 here]

133	We have detailed participants' demographic and clinical characteristics in Table 1. Briefly, all
134	PwD were above age 62 years and all study partners were above age 42. Of the PwD, 42%
135	(n=8) had hearing impairment only; 58% (n=11) had both vision and hearing impairment;
136	and none had vision impairment alone. There was an equal proportion of PwD due to
137	Alzheimer disease and vascular dementia; and one individual had 'mixed' dementia.
138	Description of the intervention
139	The basic SI comprised: a clinical vision and/or hearing assessment with prescription and
140	fitting of corrective lenses, provided by Essilor International ¹⁵ , and/or hearing aids ('behind
141	the ear' Muse Mini i2400), provided by Starkey Hearing Technologies ¹⁶ , and information
142	about device maintenance. The extended SI comprised additional components, delivered by
143	a Sensory Support Therapist (SST) in the participant's own home: (1) individualised
144	adherence support; (2) communication training; (3) functional assessment and goal-setting;
145	(4) referral to health and social care services; (5) supplementary sensory aids to enhance the
146	home environment; and (6) fostering social inclusion. The SST was an occupational therapist
147	skilled in dementia who received additional training in hearing and vision rehabilitation.
148	

148

149 Study procedures

The detailed study protocol and schedule of events are described elsewhere¹³ and shown in
Figure 1 in abbreviated form. Briefly, after informed consent, we screened PwD for hearing,
vision and cognitive impairment using the Sivantos Siemens HearCheck screener¹⁷, Peek
Acuity app¹⁸, and MoCA ¹⁹, followed by a baseline assessment and the intervention. The

154	basic SI was delivered over 4 weeks at all three sites to enable us to evaluate feasibility of
155	study procedures. At Site M, the extended SI, delivered over 12 weeks in participants'
156	homes, enabled us to evaluate further study procedures, feasibility of the intervention
157	delivery, and its acceptability and tolerability.
158	[add Figure 1 here]
159	Evaluation framework
160	We based our evaluation on a modified version of the ACCEPTANCE framework for
161	feasibility studies ²⁰ . Data were captured at baseline and within one week of the last
162	intervention visit. At each visit for the extended SI, PwD and study partners completed
163	diaries with in-house Likert-type scales (rating each aspect of acceptability and tolerability
164	on a scale of 1=strongly disagree to 5= strongly agree) and space for free text, and the SST
165	completed a log book and field notes. We conducted semi-structured interviews with a sub-
166	sample of dyads at sites M and N who received either the basic (n=8 dyads) or extended
167	(n=2 dyads) SI. The focus of the interviews was on participants' perception, experiences and
168	acceptance of the SI.
169	
170	Feasibility of trial procedures: These included our recruitment strategy, suitability of
171	eligibility criteria, execution of the 'logistics circuit' for assessment and supply of hearing
172	aids and glasses, feasibility of the participant diaries, data collection methods, suitability of

Described in detail elsewhere¹³, effectiveness measures for the PwD were: quality of life, mental wellbeing, neuropsychiatric symptoms, functional ability (dementia-, hearing- and vision-related), and relationship satisfaction. Effectiveness measures for the study partner

the battery of effectiveness measures, and retention.

173

177	were: wellbeing, mental health, caregiving-related burden and stress, and relationship
178	satisfaction. Health care resource use questionnaires were included. Since this was an
179	open-label study, we did not evaluate randomisation and blinding procedures.
180	Feasibility of the intervention components and implementation: To determine whether the
181	intervention was delivered, received and enacted as intended ²¹ , we obtained SST visit
182	completion rates, visit duration and SST logbook feedback.
183	
184	Acceptability of the intervention: The appropriateness of the delivery and receipt of the
185	intervention ²² was determined by: percentage dropouts due to non-acceptability and rate of
186	serious adverse events. The 'acceptability' criterion for the extended SI was 100% of
187	participants scoring within the <i>a priori</i> target ranges on a five point Likert-type scale: $\geq 3/5$
188	for 'understanding', 'interest', 'emotional response', 'motivation' and 'sense of
189	achievement'.
190	
191	Tolerability of the intervention: This was operationalised by percentage dropouts due to
192	intolerance of the intervention and diary ratings of 'effort' and 'fatigue' for the extended SI.
193	The criterion for 'tolerability' was 75% of participants scoring the intervention with the a
194	priori target ranges: \geq 3/5 for 'effort' and 'fatigue'.
195	
196	Data analysis
197	We used descriptive statistics for the quantitative analysis since the study was not formally

198 powered to detect specific post-intervention effect sizes. The small sample size increases

the likelihood of a Type II error when using inferential statistics. We applied content

- analysis²³, a reliable method of analysing of qualitative data using 'coding units', to the non-
- 201 quantitative data from the semi-structured interviews, participant dyad diaries, researcher
- 202 field notes and SST logbooks.

203 Results

- 204 Details of the feasibility of trial procedures and acceptability and tolerability of the
- 205 intervention are outlined in Supplementary Table S1.
- 206 Feasibility of the trial procedures
- 207 (a) Recruitment and retention

208 Recruitment was successful in Sites M and N, but slower in Site N (2.6 dyads per month for 3

209 months and 1.3 dyads per month for 6 months, respectively) and did not reach target in Site

B, which recruited 3 dyads. This resulted in a total sample size of 19 dyads from an intended

sample of 24 dyads. The retention rate at Site M was 87.5% (one participant dyad withdrew

- due to study-related burden) and at Site N was 100%. All three dyads at Site B did not
- 213 complete the study. Non-completion and failure to recruit at Site B was due to the lack of a
- 214 pathway between the study site and the necessary referral sources and lack of
- 215 infrastructure to support the logistics circuit. Screening and baseline visits were conducted
- according to protocol in all sites.

217

- 218 (b) Suitability of eligibility criteria
- 219 Investigators at all sites perceived that the cognitive score cut-off threshold (MoCA ≥12) was
- too high and would potentially exclude PwD who could meaningfully participate.

221	Additionally, of the 19 PwD who screened positive for hearing impairment, the assessing
222	audiologist did not prescribe hearing aids for five of the participants due to mildness of
223	impairment. None of these PwD received the extended intervention. All other
224	inclusion/exclusion criteria were considered appropriate by investigators.
225	
226	(c) Execution of the service and device logistics circuit
227	Referrals to vison and/or audiology assessments post-baseline visit were successful
228	although we experienced some delays and variation across study sites, with delivery of
229	glasses ranging from 7-9 weeks and hearing aids 3-20 weeks post-baseline. Delays in the
230	logistics circuit impacted on the study timeline, with post-intervention assessments being
231	conducted 7-25 weeks post-baseline. Reasons for delay were clearly identified, including
232	difficulties in arranging study visits, inadequate communication among assessing clinicians
233	and the study team, and delays in delivery of devices from suppliers.
234	
235	(d) Usability of study materials and suitability of effectiveness battery
236	Diary use by dyads was feasible and acceptable, with a 95% completion rate of entries for
237	PwD and 97% for the study partners. The battery of effectiveness measures was feasible and
238	well-tolerated, except for the self-efficacy and self-reported hearing and vision impairment
239	scales, which were difficult for the PwD to report on due to deteriorating insight. Missing
240	data on effectiveness scales for study completers was minimal (<10%) and within the a
241	priori acceptability threshold (see Supplementary Table S1).
242	Feasibility of the intervention components and implementation

We achieved 100% adherence to the study protocol for the basic SI at Sites M and N for 243 study completers. At Site B, study procedures were not completed due to problems with the 244 study team, thus we could not evaluate feasibility at this site. At Site M, 100% of 245 246 components of the extended SI were delivered, received and enacted as intended, over a range of 7-12 sessions (median 9), and a median session duration of 95 minutes (range 45-247 135). This included certain iterative changes to the intervention recorded in the SST 248 249 logbook. This number of sessions, together with the need to schedule vision and hearing 250 assessments and wait for delivery of sensory aids, required 20 weeks for full intervention 251 package to be delivered.

252

253 Acceptability and tolerability of the intervention

254 At Sites M and N there were no withdrawals due to lack of acceptability of the basic or extended SI. At site M, one dyad withdrew due poor tolerability of the extended SI (Table 2, 255 participant 4). All adverse events were classified as 'mild', including poor fit or discomfort 256 257 from corrective devices. This included expressions of concern about the potential to lose or 258 damage the corrective device, resulting in anxiety of a mild level. No serious adverse events 259 were experienced. For the extended SI, Likert-style mean acceptability ratings of 260 'understanding', 'motivation', 'emotional response', 'interest' and 'sense of achievement' all fell within the target range, as did tolerability ratings of 'effort' and 'fatigue' (Supplementary 261 262 Table S1 and Table 2). Themes emerging from the post-intervention semi-structured 263 interviews were: (1) good acceptability of session duration; (2) home-based delivery was 264 acceptable, convenient and desirable; (3) additional SST support was 'extremely helpful' in 265 encouraging the introduction of the corrective devices and optimising activity engagement;

and (4) study evaluation procedures were burdensome for some dyads because it was

267 challenging for the PwD to distinguish between their different impairments.

268

[Insert Table 2 here]

269 **Discussion**

270 This is the first reported study of a hearing and vision intervention in PwD, demonstrating 271 that such an intervention is feasible as a home-based therapy, with slight modifications, in 272 two of the three study sites. We ascertained that the intervention itself is acceptable to and 273 tolerated by PwD and their study partners. We identified the need for modifications to the study design for a full clinical trial, including: tightening the logistics circuit, widening the 274 275 recruitment pool, replacing the under-recruiting site, changing certain effectiveness 276 measures and altering the inclusion criteria for level of cognitive impairment to MoCA \geq 10. 277 Since most of the outcome measures are informant-rated or proxy-rated, it will be possible to capture accurate data for this group of participants. Diary feedback on participant 278 279 fatigue, effort and motivation and other parameters allowed fine-tuning of the intervention, and underscored the need for careful tailoring to individualised requirements, an approach 280 consistent with the conduct of pragmatic trials²⁴. We have incorporated all modifications 281 282 into a final protocol for a full RCT. We have addressed the recruitment and retention problems at Site B by replacing it with a new site in Dublin, which has a dedicated dementia 283 284 service a proven record of successful recruitment to non-pharmacologic RCTs. Furthermore, using the experience of this feasibility study, we have selected a further two European 285 dementia services (Athens and Nice) with similarly strong research experience to participate 286 in the full SENSE-Cog RCT (ISRCTN 17056211)¹¹, making five sites in total. The experience in 287 288 this study enabled us to develop robust site selection criteria for the additional sites. Finally,

289	a limitation of this study was the extended SI was only delivered in one of the field trial
290	sites, but this gave us rich data from which to develop the final extended SI for the RCT.
291	In summary, this is the first study combining hearing and vision remediation in PwD and the
292	positive feasibility, acceptability and tolerability findings suggest that a full-scale efficacy
293	trial with certain modifications is achievable.
294	Acknowledgements
295	Conflict of interest
296	HA and SF are employed by Starkey Hearing Technologies, SMa and SMo are employed by
297	Essilor International. There are no other conflicts of interest.
298	
299	Authors' contributions
300	
301	IL and PD are the programme leads and conceptualised and designed the field trial. EH is the
302	Senior Sensory Support Therapist. ZS and APC are research assistants. JR was study
303	coordinator for the field trial. RE and EC provided health economic input. MH and DR
304	provided statistical input for the study. IH and LW led the qualitative analysis. CH and FoC
305	oversaw study delivery in their sites. FiC and EF were involved in the study design and
306	interpretation of study results. CT, HA, SF, SMa and SMo provided professional input to the
307	design and conduct of the trial. EH, ZS and IL took primary responsibility for writing the
308	paper; all authors were involved in critical revision of the article.
309	
310	We thank Christine Dickinson, University of Manchester for assisting with the design of the
311	study. We thank our industry collaborators at The Outside Clinic, Starkey Hearing

312	Tech	nologies, Essilor International, Siemens Hearing Aids, Sivantos Limited (HearCheck) and
313	PEEK	Vision Limited (PEEK Acuity). We thank the Greater Manchester NIHR Clinical Research
314	Netw	ork and Greater Manchester Mental Health Trust (GMMH) for supporting the study.
315	We t	hank the Research User Group for input on the design and development of the
316	inter	vention and participants and their families for taking part in the study.
317		
318	Spon	sor's role
319	This	work was supported by the European Union's Horizon 2020 research and innovation
320	prog	ramme under grant agreement No 668648.
321		
322	Refe	rences
323	1.	Bowen M, Edgar DF, Hancock B, et al. The Prevalence of Visual Impairment in People
324		with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60–89
325		years with dementia and qualitative exploration of individual, carer and professional
326		perspectives. Heal Serv Deliv Res. 2016;4(21):1-200. doi:10.3310/hsdr04210
327	2.	Lin FR, Metter EJ, O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L. Hearing loss and
328		incident dementia. Arch Neurol. 2011;68(2):214-220.
329	3.	Leroi I, Pye A, Armitage CJ, et al. Research protocol for a complex intervention to
330		support hearing and vision function to improve the lives of people with dementia.
331		<i>Pilot Feasibility Stud</i> . 2017;3(1):1-16. doi:10.1186/s40814-017-0176-1
332	4.	Guthrie DM, Davidson JGS, Williams N, et al. Combined impairments in vision, hearing
333	7.	and cognition are associated with greater levels of functional and communication

- difficulties than cognitive impairment alone: Analysis of interRAI data for home care
 and long-term care residents in Ontario. *PLoS One*. 2018;13(2):e0192971.
 doi:10.1371/journal.pone.0192971
- 337 5. Lawrence V, Murray J, Ffytche D, Banerjee S. The experiences and needs of people

338 with dementia and serious visual impairment: a qualitative study. Int

339 *Psychogeriatrics*. 2009;21(3):511-518. doi:10.1017/S1041610209008424

- 340 6. Nyman SR, Innes A, Heward M. Social care and support needs of community-dwelling
- 341 people with dementia and concurrent visual impairment. *Aging Ment Health*.
- 342 2017;21(9):961-967. doi:10.1080/13607863.2016.1186151
- 343 7. Ke KM, Montgomery A-M, Stevenson M, O'Neill C, Chakravarthy U. Formal and
- 344 informal care utilisation amongst elderly persons with visual impairment. Br J

345 *Ophthalmol.* 2007;91(10):1279-1281. doi:10.1136/bjo.2006.113142

- 346 8. Dawes P, Wolski L, Himmelsbach I, Regan J, Leroi I. Interventions for hearing and
- 347 vision impairment to improve outcomes for people with dementia: A scoping review.
- 348 *Int Psychogeriatrics*. 2018:1-19. doi:10.1017/S1041610218000728
- 349 9. Hartley D, Rochtchina E, Newall P, Golding M, Mitchell P. Use of hearing AIDS and
- assistive listening devices in an older Australian population. *J Am Acad Audiol*.
- 351 2010;21(10):642. doi:10.3766/jaaa.21.10.4
- 352 10. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and
- 353 evaluating complex interventions: the new Medical Research Council guidance. Br
- 354 *Med J.* 2008;337:a1655. doi:10.1136/bmj.a1655

355	11.	Regan J, Frison E, Collin F, et al. Individualised sensory intervention to improve quality
356		of life in people with dementia and their companions (SENSE-Cog trial): study
357		protocol for a randomised controlled trial. <i>Trials</i> . 2019;20:80(1):1-15.
358		doi:10.1186/s13063-018-2973-0
359	12.	Join Dementia Research. www.joindementiaresearch.nihr.ac.uk.
360	13.	Regan J, Dawes P, Pye A, et al. Improving hearing and vision in dementia: Protocol for
361		a field trial of a new intervention. BMJ Open. 2017;7(11):1-12. doi:10.1136/bmjopen-
362		2017-018744
363	14.	Department of Health. <i>Mental Capacity Act</i> . London; 2005.
364	15.	Essilor International. https://www.essilor.com/en/.
365	16.	Starkey Hearing Technologies. https://www.starkey.com/.
366	17.	Sivantos Siemens Hearcheck. https://www.bestsound-
367		technology.co.uk/nhs/equipment/hear-check/.
368	18.	Peek Vision. https://www.peekvision.org/.
369	19.	Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment,
370		MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc.
371		2005;53(4):695-699.
372	20.	Charlesworth G, Burnell K, Hoe J, Orrell M, Russell I. Acceptance checklist for clinical
373		effectiveness pilot trials: a systematic approach. BMC Med Res Methodol.
374		2013;13(78):1-7. doi:10.1186/1471-2288-13-78

375	21.	Burgio L, Corcoran M, Lichstein KL, et al. Judging outcomes in psychosocial
376		interventions for dementia caregivers: The problem of treatment implementation.
377		Gerontologist. 2001;41(4):481-489. doi:10.1093/geront/41.4.481
378	22.	Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: An
379		overview of reviews and development of a theoretical framework. BMC Health Serv
380		Res. 2017;17(1):1-13. doi:10.1186/s12913-017-2031-8
381	23.	Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health
382		Res. 2005;15(9):1277-1288.
383	24.	Hawe P, Shiell A, Riley T. Complex interventions: how "out of control" can a
384		randomised controlled trial be? <i>Br Med J</i> . 2004;328(June):1561-1563.
385	25.	Chen G, Gully S, Eden D. Validation of a New General Self-Efficacy Scale. Organ Res
386		Methods. 2001;4(1):62-83. doi:10.1177/109442810141004
387	26.	Yesavage JA. Geriatric depression scale. <i>Psychopharmacol Bull</i> . 1988;24(4):709-711.
388	27.	Burns DD. Ten Days to Self-Esteem: The Leader's Manual. Quill/HarperCollins
389		Publishers; 1993.
390	28.	Zigmond A, Snaith R. The Hospital Anxiety and Depression Scale. Acta Psychiatr
391		Scand. 1983;67:361-370.

- 393 Legends
- 394 Figure 1: Flowchart of study procedures (submitted separately as a TIF file)

396

397 Table 1 Description of the baseline demographic and clinical variables in participants with

398 dementia and their study partners


399

Variable	Category	Participants with Dementia	Study partner Participants	
N			19	
	Median (IQR)	76 (11)	67 (13)	
Age (Years)	Range	63 to 88	43 to 82	
	Female	7 (36.8%)	16 (84.2%)	
Gender	Male	12 (63.2%)	3 (15.8%)	
Duration of		· · ·		
Cognitive	Median (IQR)	60 (54)	NA	
Impairment	Range	6 to 120	NA	
(Months)				
Level of Cognitive	Mean (SD)	17.3 (3.7)		
Impairment	Range	17.3 (3.7) 12 to 23	NA	
(MoCA Total Score)	Kange	12 (0 23		
	Alzheimer's	9 (47.4%)		
Dementia Sub-Type	Vascular	9 (47.4%)	NA	
	Mixed	1 (5.3%)		
	Hearing only	8 (42.1%)		
Sensory Impairment	Vision only	0	NA	
	Hearing & Vision	11 (57.9%)		
	Spouse/ Partner		13 (68.4%)	
Relationship to PwD	Son/ Daughter	NA	5 (26.3%)	
	Other Relative		1 (5.3%)	
Hours per Week	Median (IQR)	NIA	100 (115)	
spent with PwD	Range	NA	3 to 168	

400 SD: standard deviation; IQR: interquartile range

401

403 Figure 1: Flowchart of study procedures



		Ratings of SI vis	sits by PwD, stud	y partner and S	ST: Mean
		score (range)			
		Participant 1 Participant 2 Participant 3 Participant 4			
Acceptability	Understanding ^{PwD}	4.7 (4-5)	4.6 (4-5)	3.1 (2-4)	3.3 (2-5)
	Motivation PwD	4.6 (4-5)	4.9 (4-5)	3.9 (3-5)	3.3 (2-4)
	Motivation SP	4.4 (4-5)	5 (5-5)	3.3 (2-4)	3.8 (3-4)
	Motivation SST	4 (4-4)	4.8 (4-5)	3.3 (2-4)	4.5 (4-5)
	Sense of	4.4 (4-5)	4.7 (4-5)	3 (2-5)	3.5 (3-4)
	achievement ^{SP}				
	Sense of	3.8 (3-4)	4.6 (4-5)	3.1 (2-4)	4 (3-5)
	achievement ^{SST}				
	Interest SP	4.7 (4-5)	5 (5-5)	3.6 (3-4)	3.8 (3-4)
	Interest SST	4 (4-4)	4.8 (4-5)	3.8 (2-4)	4.8 (4-5)
	Emotional	4.1 (4-5)	4.4 (4-5)	3.1 (2-4)	3.3 (3-4)
	response ^{SP}				
Tolerability	Effort ^{PwD}	4.7 (4-5)	4.5 (4-5)	3.1 (2-5)	2.3 (1-4)
	Fatigue ^{PwD}	5 (5-5)	3.2 (2-5)	3.4 (1-4)	1.5 (1-2)

405 **Table 2 Acceptability and tolerability of the extended Sensory Intervention***

406 Key: ^{PwD} PwD rating of response; ^{SP} Study partner rating of PwD's response; ^{SST}SST rating of 407 PwD's response.

408 * Rated by participants on a 5-point Likert-type scale: 1=strongly disagree; 2=disagree;

409 3=neutral; 4=agree; 5=strongly agree (reverse rating for 'effort' and 'fatigue').

411 Supplementary Table S1: Feasibility of trial procedures and intervention feasibility,

412 acceptability and tolerability

Parameter and <i>a priori</i> evaluation criteria (if applicable)	Findings	Evidence to support finding	Changes implemented for RCT
Feasibility of study proc	edures		
Eligibility criteria: ≥75% screened meet study criteria	Criteria are acceptable except: (1) cognitive score cut-offs may be set too high and exclude PwD who may be appropriate; (2) HearCheck screening cut-off may not be stringent enough.	 100% of those screened met inclusion criteria^a. 5 participants who screened positive on hearing impairment using the HearCheck were deemed not clinically suitable for hearing aids on full assessment^a. There was an imbalance of sensory diagnostic groupings across the sites^a. 	Inclusion criteria adjusted to MoCA ≥10. Remaining components of the SI will continue for any PwD not prescribed sensory aids following clinical assessment.
Recruitment: Total target number Rate	Successful at 2 of 3 sites. Slower than required for a larger trial.	100% at Site M and N; 38% at Site B ^a . Rate was 2.7 dyads per month at Site M and 1.3 dyads per month at Site N ^a . Incomplete recruitment at Site B.	Site B replaced with an alternative. Recruitment pool widened.
Retention: ≥60% completed all study procedures	Successful in 2 of 3 sites.	93.8% completed the study in Sites M and N; 0% completed in Site B ^a .	Site B replaced with an alternative.
Screening & baseline process:	Appropriate due to the length of assessment battery.	9 dyads had one visit; 10 had two visits ^ª .	No changes indicated.
Outcome battery administration and suitability: ≥10% missing data suggests scale is not acceptable	Outcome rating scales are generally acceptable. Some scales were not suitable for the study population and require	<10% missing data from outcome rating scales at baseline and follow-up ^a . Missing items within given scales included gender- specific physiological	General Self Efficacy Scale ²⁵ dropped. Geriatric Depression Scale ²⁶ replaced with the Hospital Anxiety and Depression Scale ²⁸ .

revision. items ^a . Caregiver reports of Minimal or no hearing and vision concerns were noted impairment introdu on battery duration alongside PwD's se and level of difficulty, report. other than all 3 sites reporting problems Relationship	
Minimal or no hearing and vision concerns were noted impairment introdu on battery duration alongside PwD's se and level of difficulty, other than all 3 sites	
concerns were noted impairment introduced on battery duration alongside PwD's see and level of difficulty, report. other than all 3 sites	iced
on battery duration alongside PwD's se and level of difficulty, report. other than all 3 sites	
and level of difficulty, report. other than all 3 sites	
other than all 3 sites	
reporting problems Relationship	
with: Satisfaction Scale ²⁷	
PwD understanding procedure amende	d
the General Self	u.
Efficacy Scale ²⁵ items ^b ;	
The Geriatric	
Depression Scale ²⁶ was	
not appropriate for	
younger study partners ^a ;	
PwD self-report of	
hearing and vision	
impairment was not	
valid ^a .	
The Relationship	
Satisfaction Scale ²⁷ was	
difficult to administer	
in presence of the	
study partner ^b	
Device logistics circuit: Broadly feasible; areas All prescribed hearing Logistics circuit	
for improvement aids and glasses were tightened through	
identified. received by training and	
participants ^a . identification of	-
dedicated clinician Delays in assessment	5.
for and receipt of Timeframe for SI	
corrective devices delivery extended.	
impacted on overall	
study timelines ^a .	
Participant diary: Diary activity was 95% of diary entries No changes indicat	ed.
280% completion feasible for both PwD completed by both	
and study partner. members of the dyad ^c .	
Feasibility of the Sensory Intervention (SI) components and	
mplementation:	
Basic SI: Basic intervention (Sites M, N and B)	
Extended SI: Extended intervention (Site M)	
Basic SI: It is feasible, although 100% of participants Logistics circuit	
Was the basic SItimeline deviationsreceived a vision and /tightened up.	
delivered, received and were evident. or hearing assessment	
enacted as intended? and prescription of Window for vision	/

		corrective devices (if indicated) within 20 weeks of baseline ^a . 100% of participants completed measures of device skills and knowledge (hearing aids / glasses) ^a .	hearing assessment specified as 1-8 weeks from randomisation.
Extended SI: Completion of extended SI within 12 weeks	It is feasible to complete the SI within 12 visits. The timeline of 12 weeks was not feasible due to logistics circuit delays and participant / SST availability. Successful delivery of each component is possible. It is viable to introduce the SI components in a flexible manner to account for delays in receiving hearing aids / glasses.	SI was completed over a mean of 9 visits (range 7-12) ^b . Time from baseline to follow-up was mean 18 weeks (range 17-20) ^a . 100% of participants completed functional assessment and set study-related goals ^b ; of those that continued the SI to completion, 100% of components were addressed ^b . Elements of the extended SI were successfully introduced prior to device delivery ^b .	Timeframe extended from 12 weeks to 18 weeks for SI delivery.
Acceptability of the inte	ervention:		
Basic SI: Was the Sensory Intervention appropriate?	The basic intervention is acceptable	100% of participants were willing to receive their prescribed aids ^a . No participant withdrawals due to lack of acceptability ^a .	No changes indicated.
Extended SI: 100% of: Score ≥ 3 on PwD scales for understanding and motivation Score ≥ 3 on SP and SST scales for motivation and sense	The intervention is broadly acceptable. PwD may not demonstrate anticipated levels of sense of achievement; however there were no withdrawals due to lack of acceptability.	100% of mean scores are within range for PwD ^c . 100% of mean scores are within range for SP and SST ^{b,c} .	No changes indicated.

of achievement Score ≥ 3 on SP and SST scales for interest and emotional response			
Tolerability of the interv	ention by participants:		
Basic SI:	The basic intervention is tolerable	100% of participants were able to complete their vision and / or hearing assessment ^a . The basic intervention	No changes indicated.
		was completed over maximum 3 visits ^a .	
Extended SI: 75% of: Score ≥ 3 on PwD scale for effort and fatigue	The intervention is broadly tolerable but the SST needs to be mindful that lower tolerability ratings could indicate withdrawal risk.	One participant withdrew after 4 SI visits due to perceived burden (Participant 4). This is reflected in their effort and fatigue scores ^c .	SST to monitor diary responses and tailor the SI to the PwD's needs.
		75% of scores were ≥3. This is within the <i>a</i> <i>priori</i> range for tolerability.	

414 Key PwD = Person with dementia; SP= Study Partner; SST= Sensory Support Thera

^a Quantitative data; ^b SST logbook; ^c Participant dyad diaries